{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:23:01Z","timestamp":1762507381807,"version":"3.41.0"},"reference-count":18,"publisher":"Japanese Society of Internal Medicine","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2018,8,1]]},"DOI":"10.2169\/internalmedicine.9885-17","type":"journal-article","created":{"date-parts":[[2018,3,29]],"date-time":"2018-03-29T22:23:20Z","timestamp":1522362200000},"page":"2169-2178","source":"Crossref","is-referenced-by-count":5,"title":["The Efficacy of Minodronate in the Treatment of Glucocorticoid-induced Osteoporosis"],"prefix":"10.2169","volume":"57","author":[{"given":"Eriko","family":"Hasegawa","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Niigata Rheumatic Center, Japan"},{"name":"Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Niigata Rheumatic Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chinatsu","family":"Takai","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Niigata Rheumatic Center, Japan"},{"name":"Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Niigata Rheumatic Center, Japan"},{"name":"Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumi","family":"Nomura","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Niigata Rheumatic Center, Japan"},{"name":"Department of Orthopedic Surgery, Kagawa University Faculty of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Otani","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Niigata Rheumatic Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asami","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Niigata Rheumatic Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajime","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Niigata Rheumatic Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Murasawa","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Niigata Rheumatic Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiei","family":"Narita","sequence":"additional","affiliation":[{"name":"Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Nakazono","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Niigata Rheumatic Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Manolagas SC, Weistein RS. New developments in the pathogenesis and treatment of steroid-induced osteoporosis. J Bone Miner Res 14: 1061-1066, 1999.","DOI":"10.1359\/jbmr.1999.14.7.1061"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13: 777-787, 2002.","DOI":"10.1007\/s001980200108"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Buckley L, Guyatt G, Fink HA, et al. 2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res 69: 1095-1110, 2017.","DOI":"10.1002\/acr.23279"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 339: 292-299, 1998.","DOI":"10.1056\/NEJM199807303390502"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Cohen S, Levy RM, Keller M, et al. Risedronate therapy prevents corticosteroid-induced bone loss. Arthritis Rheum 42: 2309-2318, 1999.","DOI":"10.1002\/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Hagino H, Shiraki M, Fukunaga M, et al. Three years of treatment with minodronate in patients with postmenopausal osteoporosis. J Bone Miner Metab 30: 439-446, 2012.","DOI":"10.1007\/s00774-011-0332-2"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Matsumoto T, Hagino H, Shiraki M, et al. Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study. Osteoporos Int 20: 1429-1437, 2009.","DOI":"10.1007\/s00198-008-0816-7"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Kitamura N, Shiraiwa H, Inomata H, et al. Efficacy and safety of minodronic acid hydrate in patients with steroid-induced osteoporosis. Int J Rheum Dis, 2016 (Epub ahead of print).","DOI":"10.1111\/1756-185X.12844"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Ebina K, Noguchi T, Hirao M, et al. Effects of switching weekly alendronate or risedronate to monthly minodronate in patients with rhumatoid arthritis: a 12-months prospective study. Osteoporos Int 27: 351-359, 2016.","DOI":"10.1007\/s00198-015-3369-6"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Suzuki Y, Nawata H, Soen S, et al. Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research. J Bone Miner Metab 32: 337-350, 2014.","DOI":"10.1007\/s00774-014-0586-6"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Dunford JE, Thompson K, Coxon FP, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 296: 235-242, 2001.","DOI":"10.1016\/S0022-3565(24)38786-5"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Takeuchi M, Sakamoto S, Kawamuki K, et al. Studies on novel bone resorption inhibitors II. Synthesis and pharmacological activities of fused aza-heteroarylbisphosphonate derivatives. Chem Pharm Bull 46: 1703-1709, 1998.","DOI":"10.1248\/cpb.46.1703"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Sakai A, Ikeda S, Okimoto N, et al. Clinical efficacy and treatment persistence of monthly minodronate for osteoporotic patients unsatisfied with, and shifted from, daily or weekly bisohosphonates: the BP-MUSASHI study. Osteoporos Int 25: 2245-2253, 2014.","DOI":"10.1007\/s00198-014-2756-8"},{"key":"14","unstructured":"14. Kamimura M, Ikegami S, Hirabayashi H, et al. Analysis on clinical effect (Bone Turn over Marker and Bone Mineral Density) of minodronate and risedronate in primary osteoporosis. Shinyaku to Rinsyou 61: 149-156, 2012 (in Japanese)."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Leslie WD, Tsang JF, Caetano PA, et al. Effectiveness of bone density measurement for predicting osteoporotic fractures in clinical practice. Clin Endocrinol Metab 92: 77-81, 2007.","DOI":"10.1210\/jc.2006-1415"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Stone KL, Seeley DG, Lui LY, et al. BMD at multiple sites and risk of fracture of multiple types: long-term results from the study of osteoporotic fractures. Bone Miner Res 18: 1947-1954, 2003.","DOI":"10.1359\/jbmr.2003.18.11.1947"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Johnell O, Kanis JA, Oden A, et al. Predictive value of BMD for hip and other fractures. Bone Miner Res 20: 1185-1194, 2005.","DOI":"10.1359\/JBMR.050304"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Haugeberg G, Bjorn K, Forre O, et al. Generalized bone loss in early rheumatoid arthritis patients followed for ten years in the biologic treatment era. BMC Musculoskelet Disord 15: 289, 2014.","DOI":"10.1186\/1471-2474-15-289"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/15\/57_9885-17\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T03:18:22Z","timestamp":1751512702000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/15\/57_9885-17\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,1]]},"references-count":18,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.9885-17","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"type":"print","value":"0918-2918"},{"type":"electronic","value":"1349-7235"}],"subject":[],"published":{"date-parts":[[2018,8,1]]}}}